What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis

What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis

Carmen Fucile,1 Francesca Mattioli,1 Valeria Marini,1 Massimo Gregori,2 Aurelio Sonzogni,3 Antonietta Martelli,1 Natalia Maximova4 1Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy; 2Department of Pediatric Radiology, Institute for Maternal and Child Health – IRCCS Burl...

Full description

Bibliographic Details
Main Authors:	Fucile C, Mattioli F, Marini V, Gregori M, Sonzogni A, Martelli A, Maximova N
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-09-01
Series:	Therapeutics and Clinical Risk Management
Subjects:	deferasirox allogeneic hematopoietic stem cell transplantation (allo-HSCT) pediatric ductopenia therapeutic drug monitoring adverse events
Online Access:	https://www.dovepress.com/what-is-known-about-deferasirox-chelation-therapy-in-pediatric-hsct-re-peer-reviewed-article-TCRM

Similar Items

Encephalitozoon intestinalis: A Rare Cause of Diarrhea in an Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Recipient Complicated by Albendazole-Related Hepatotoxicity
by: Serdar Şıvgın, et al.
Published: (2013-06-01)

Donor and Recipient Individual Factors as Predictive Markers of Overall Survival After Allogeneic Hematopoietic Stem Cell Transplantation; Dream or Reality
by: Pooya Eslampour, et al.
Published: (2021-02-01)

Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies
by: Nancy Y. Villa, et al.
Published: (2016-03-01)

High Throughput Analysis Reveals Changes in Gut Microbiota and Specific Fecal Metabolomic Signature in Hematopoietic Stem Cell Transplant Patients
by: Soumaya Kouidhi, et al.
Published: (2021-08-01)

Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
by: Laura Galeotti, et al.
Published: (2021-08-01)

Graft failure in allogeneic hematopoietic stem cell recipients: diagnosis and treatment
by: U. V. Maslikova, et al.
Published: (2023-03-01)

Efficacy and safety of blinatumomab for the treatment of patients relapsing after allogeneic hematopoietic cell transplantation: a systemic review and meta-analysis
by: Huai-Peng Guo, et al.
Published: (2024-12-01)

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS
by: Elena Maria Elli, et al.
Published: (2014-05-01)

Selection of hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma
by: Zhen Li, et al.
Published: (2023-07-01)

Influence of platelet antigens differences between donor and recipient on neutropenia and thrombocytopenia duration after allogeneic stem cell transplantation
by: L. L. Golovkina, et al.
Published: (2022-11-01)

Improved survival outcomes and restoration of graft‐vs‐leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia
by: Byung‐Sik Cho, et al.
Published: (2019-02-01)

Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study
by: Weihao Chen, et al.
Published: (2024-04-01)

COVID-19 infection in hematopoietic stem cell transplant recipients
by: Siniaev A.A., et al.
Published: (2022-09-01)

Efficacy and safety of hetrombopag in the treatment of recombinant human thrombopoietin–resistant thrombocytopenia after allogeneic hematopoietic stem cell transplantation
by: Jing Ni, et al.
Published: (2024-10-01)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
by: Xing-yu Cao, et al.
Published: (2023-12-01)

Low incidence and morbidity of Epstein‐Barr virus reactivation following donor lymphocyte infusions
by: Danilo Martinovic, et al.
Published: (2023-05-01)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
by: Zhangjie Chen, et al.
Published: (2023-03-01)

Allogeneic hematopoietic stem cell transplant for HIV patient's plasmablastic lymphoma: Case report
by: Marco Ruiz, et al.
Published: (2023-03-01)

Prevention and management of human cytomegalovirus in pediatric HSCT recipients: A review
by: Lisa Hiskey, et al.
Published: (2022-11-01)

Influence of ESBL colonization status on gut microbiota composition during allogenic hematopoietic stem cell transplantation
by: Silvia Corcione, et al.
Published: (2025-01-01)

Clinical outcomes and early immune reconstitution in patients with acute lymphoblastic leukemia underwent allogeneic hematopoietic stem cell transplantation
by: Huiyu LI, et al.
Published: (2023-09-01)

PRT to predict pharmacokinetic profiles as part of a bioequivalence study of the drug deferasirox
by: A. V. Suvorova, et al.
Published: (2024-09-01)

Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China
by: Hongye Gao, et al.
Published: (2024-08-01)

Desensibilización a deferasirox en una paciente con hemocromatosis. Reporte de un caso
by: Nadia Karina Aguilar Hinojosa, et al.
Published: (2023-08-01)

Torque Teno Virus Viral Load as a Marker of Immune Function in Allogeneic Haematopoietic Stem Cell Transplantation Recipients
by: William Mouton, et al.
Published: (2020-11-01)

Combination iron chelation therapy with deferiprone and deferasirox in iron-overloaded patients with transfusiondependent β-thalassemia major
by: Hossein Karami, et al.
Published: (2017-01-01)

Long-term survivors demonstrate superior quality of life after haploidentical stem cell transplantation to matched sibling donor transplantation
by: Xiaoyu Zhang, et al.
Published: (2022-12-01)

Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
by: M. V. Barabanshchikova, et al.
Published: (2016-03-01)

Effect and mechanism of extracorporeal photopheresis on preventing acute graft versus host disease in ice
by: Zhanrui CHENG, et al.
Published: (2023-10-01)

The Impact of Achieving Complete Remission Prior to Allogeneic Stem Cell Transplantation on Progression-Free Survival in Hodgkin Lymphoma
by: Nadira Duraković, et al.
Published: (2021-07-01)

The predictive value of T-cell chimerism for disease relapse after allogeneic hematopoietic stem cell transplantation
by: Zhipeng Li, et al.
Published: (2024-04-01)

Prediction model for EBV infection following HLA haploidentical matched hematopoietic stem cell transplantation
by: Xun-Hong Cao, et al.
Published: (2024-03-01)

Analysis of Correlation between Body Mass Index and the Incidence of Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation
by: Masoud Soleimani, et al.
Published: (2021-09-01)

Gastrointestinal Complications after Allogeneic Hematopoietic Stem Cell Transplant: A Multidisciplinary Approach with Early Endoscopic Evaluation
by: Giuseppe Tarantino, et al.
Published: (2021-09-01)

THE ANTIOXIDANT EFFECTS OF CAPPARIS OVATA AND DEFERASIROX IN PATIENTS WITH THALASSEMIA MAJOR
by: Handan Duman, et al.
Published: (2014-08-01)

Spectrofluorimetric Determination of Daunorubicin Using Terbium-Deferasirox as a Fluorescence Probe
by: جمشید منظوری لشگر, et al.
Published: (2015-01-01)

Comparative analysis of deferasirox and deferiprone iron chelator on the growth pattern of Bengali β-thalassemia major children of West Bengal, India
by: Isita Tripathy, et al.
Published: (2022-09-01)

Endothelial injury syndromes after hematopoietic stem cell transplantation: analyzing clinical case
by: Y. V. Skvortsova, et al.
Published: (2022-11-01)

Deferasirox Causes Leukaemia Cell Death through Nrf2-Induced Ferroptosis
by: Wan-Yi Hsu, et al.
Published: (2024-03-01)

In vitro Studying of Deferasirox Side effects on the Structure and the Function of Bovine Liver Catalase
by: Maryam Moradi, et al.
Published: (2014-11-01)